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Abstract
Background: Infarct heterogeneity, as assessed by determination of the peri-infarct zone (PIZ) by cardiac magnetic
resonance imaging, has been shown to be an independent predictor for the development of cardiac arrhythmias
and mortality post myocardial infarction (MI). The temporal evolution of the PIZ post MI is currently unknown. Thus,
the main objective of our study was to describe the temporal evolution of the PIZ over a 6 month time period in
contemporarily managed ST elevation myocardial infarction (STEMI) patients. Further, given the poor prognosis
associated with microvascular obstruction (MVO) post STEMI, we sought to compare the temporal evolution of the
PIZ in patients with and without MVO. We hypothesized that patients with MVO would show a relative persistence
of PIZ over time when compared to those without MVO.
Methods: Twenty-one patients post primary percutaneous coronary intervention were enrolled and treated with
evidence based therapy. Each patient had three cardiac MRI scans at 48 h, 3 weeks and 6 months post infarction.
Repeated Measures Analysis of Variance (ANOVA) was used to assess the evolution of core infarct size and
peri-infarct zone size across the three time frames.
Results: The patients in this study were predominantly male, with ~40 % LAD territory infarction and a mean LVEF
of 46 ± 7 %. Core infarct size and PIZ size both decreased significantly across the three time frames. The presence of
microvascular obstruction (MVO), a known adverse prognostic factor, influenced PIZ size. Both patients with and
without MVO had a significant reduction in core infarct size over time. Patients with MVO did not have a significant
change in PIZ size over time (11.9 ± 6.8 %, 12.2 ± 7.5 %, 10.7 ± 6.6 % p = 0.77). In contrast, non-MVO patients did
have a significant decrease in PIZ size over time (7.0 ± 5.5 %, 7.1 ± 6.5 %, 2.7 ± 2.6 %, p = 0.01).
Conclusions: Peri-infarct zone size, like core infarct size, varies depending upon the timing of measurement.
Patients with MVO displayed a persistence of the PIZ over time.
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Background
Cardiac magnetic resonance (CMR) imaging is consid-
ered the gold standard in the assessment of left ventricu-
lar structure and function [1, 2]. However, CMR’s major
advantage over other imaging modalities lies in its ability
to accurately detect altered tissue composition, referred
to as tissue characterization. The ability of CMR to
assess altered tissue composition has led to the identifi-
cation of tissue signatures that predict adverse outcomes.
One such measure is referred to as the peri-infarct zone
(PIZ) or ‘gray zone’, which represents an area of infarct
heterogeneity and has been shown to both correlate with
cardiac arrhythmias and to be an independent predictor
of post MI mortality [3–6]. Histological studies demon-
strate that this zone consists of distorted bundles of
surviving myocytes interweaved with extracellular matrix
creating an arrhythmogenic substrate [7, 8]. The assess-
ment of core infarct size (CIS) in the early period
following myocardial infarction using late gadolinium
enhancement (LGE) CMR may be misleading as the
combination of necrosis/apoptosis and edema can lead
to infarct size overestimation. As a result, it is suggested
that LGE-CMR be performed greater than 48 h follow-
ing acute myocardial infarction in order to accurately
assess infarct size. Given that infarct size changes post
myocardial infarction, in a temporal manner, we sought
to compare the evolution of the heterogeneous peri-
infarct zone in contemporarily managed ST elevation
myocardial infarction (STEMI) patients across three
time points – at 48 h post reperfusion, at 3 weeks and at
6 months following the index event, in order to better
elucidate the variability of this measurement. Further-
more, multiple studies have linked the presence of MRI
determined microvascular obstruction (MVO) with a
poor clinical prognosis post STEMI [9–13]. We there-
fore sought to compare the temporal evolution of the
PIZ in patients with and without MVO. We hypothe-
sized that patients with MVO would show a relative




Twenty-one patients who presented to Sunnybrook
Health Sciences Centre with STEMI were prospectively
enrolled in our study between the years 2009–2011.
Consent was obtained from all patients. The main inclu-
sion criteria was patients who had met the diagnosis of
STEMI. Exclusion criteria included failure to provide
consent, significant arrhythmias, severe renal impair-
ment (GFR <30 mL/min) as well as contraindications to
CMR imaging such as implantable cardioverter-
defibrillators and pacemakers. Six patients who had
initially agreed to participate in the study dropped out
(not included in the 21 patients mentioned above). Of
these, 3/6 dropped out due to claustrophobia, two
patients were lost to follow up and one decided not to
continue with the study after his first scan. All patients
underwent primary percutaneous coronary intervention
(primary PCI) of the culprit coronary vessel. Further, all
21 patients received standard of care post STEMI
medications including dual anti-platelet therapy, a statin
and a beta-blocker. The study was approved by the
ethics review board of Sunnybrook Health Sciences
Centre.
CMR acquisition protocol
Each patient was imaged at three time points: 48 h,
3 weeks, and 6 months post STEMI. Studies were
performed on a 1.5-T clinical scanner (Signa Twinspeed
HDx; GE Healthcare, Waukesha, WI) with image acqui-
sition performed using electrocardiographic triggering
and breath holds at end-expiration. Cardiac function
was determined using contiguous short axis slices cover-
ing the left ventricle acquired with a standard SSFP (GE
FIESTA) sequence with the following parameters: echo
time = 1.6 ms, flip angle = 45°, acquisition matrix = 256 ×
192, bandwidth = 125 kHz, and 20 cardiac phases per
slice. An inversion recovery gradient echo T1-weighted
sequence was used to assess for late gadolinium en-
hancement with the following parameters: TR = 5.5 msec,
TE = 2.5 msec, FOV = 350 × 350 mm, matrix 192 × 128.
Table 1 Characteristics of the patient population
Total (N = 21)
Age (years) 57 ± 10
Male (%) 19 (90)
Culprit vessel
Left anterior descending 8 (38)
Circumflex 5 (24)
Right coronary artery 8 (38)





Peak CK (AU) 2160 ± 1797
Door to Balloon time (mins) 73 ± 25
LVEF 46 ± 7
LVEDVi 66 ± 13
LVESVi 36 ± 9
RVEF 55 ± 12
Abbreviations used in the table
DM diabetes mellitus, LVEF left ventricular ejection fraction, LVEDVi (indexed
left ventricular end diastolic volume), LVESVi (indexed left ventricular end
systolic volume), RVEF right ventricular ejection fraction
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The inversion time was manually adjusted to null sig-
nal from normal myocardium and short-axis images
were obtained 10 min after intravenous administration
of gadolinium-diethylene triamine pentaacetic acid
(0.2 mmol/kg; Gadovist, Bayer Healthcare, Wayne,
NJ) [14–17].
CMR image analysis
Core infarct size, peri-infarct zone size and MVO were
quantified from contrast-enhanced T1-weighted images
utilizing the previously described full-width-half-max-
imum technique [14, 18, 19]. The algorithm was imple-
mented using custom-written scripts developed in
MATLAB (The Mathworks, Natick, MA). Specifically,
the infarct core was defined as myocardium with signal
intensity >50 % of the maximal myocardial signal inten-
sity. A region of interest was then drawn in the remote
myocardium (remote from the infarcted territory).
Peri-infarct zone was subsequently defined as the
myocardium with signal intensity > peak remote signal
intensity but <50 % of the maximal signal intensity in
the infarct core as described by Schmidt et al. [18].
MVO was identified as a region of hypoenhancement
within the region of the hyperenhanced infarct on late
gadolinium enhancement images and was manually
traced. It was added to the core infarct size. Both core
infarct size and peri-infarct zone were quantified as a
percentage of LV mass.
T2 quantification was performed using a previously
described free-breathing cardiac-gated spiral imaging
sequence with T2 preparation. 5 short axis slices were
equally spaced to cover the extent of the left ventricle
from apex to base. The following parameters were
utilized in this sequence; echo times = 2.9, 24.3, 88.2 and
184.2 milliseconds; 12 spiral interleaves with 4096 points
each (16.4 millisecond duration) yielding a 1.4 mm
in-plane resolution; slice thickness = 6 mm and band-
width = 125kH [17, 20].
Fig. 1 Evolution of core infarct size and peri-infarct zone (gray zone) in the entire patient population. Note, there is no difference between the
48 h and 3 week time point, whilst both reduce significantly by 6 months
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Statistical analysis
Unpaired t-tests and chi-square tests were used to com-
pare continuous and categorical variables between MVO
and Non-MVO patients respectively. Results from these
tests are displayed as means ± standard deviations (for
t-tests) and as proportions (for chi-square tests). Repeated
measures analysis of variance (ANOVA) was then used to
compare the evolution of core infarct size and peri-infarct
zone size across the three time frames. Tukey’s multiple
comparison test was performed to compare preselected
time frames (48 h vs. 3 weeks and 3 weeks vs. 6 months).
MVO is a known predictor of adverse prognosis and in-
farct size. We therefore assessed the evolution of the peri-
infarct zone, in patients with, and without MVO. In order
to assess inter-observer variability in the assessment of the
PIZ, a second experienced observer assessed one slice in
12 random patients (6 with MVO and 6 without) at the
three time frames. This was done by calculating the Pear-
son correlation coefficient comparing the first and second
observer. A Bland-Altman plot was also constructed com-
paring difference vs. average of observer 1 vs. observer 2.
A p value <0.05 was considered statistically significant.
Statistical analysis was done using GraphPad Prism 6.0
(GraphPad Software Inc., La Jolla, California).
Results
Twenty-one patients were enrolled post STEMI. Table 1
displays the characteristics of the patient population.
The mean age was 57 ± 10 years, 90 % of whom were
male with a mean door to balloon time of 73 ± 25 min,
and a peak CK of 2160 ± 1797 (IU). The mean LVEF was
46 ± 7 %. The infarcts were predominantly non-LAD ter-
ritory. Approximately 38 % of the cohort was diabetic,
48 % was hypertensive, 38 % smoked and 19 % was dys-
lipidemic (see Table 1). Figure 1 demonstrates the effect
of time upon core infarct and peri-infarct zone size in
the entire cohort. As can be seen, both core infarct size
(18.0 ± 12.7 %, 17.7 ± 13.6 %, 10.6 ± 12.4 %, p < 0.0001)
and peri-infarct zone size (9.1 ± 6.5 %, 9.4 ± 7.2 %, 6.1 ±
6.1 %, p = 0.03) decreased significantly over the three
time periods studied. Tukey’s multiple comparison test
showed that in the case of both CIS and PIZ, there was
no significant difference between the 48 h and 3 week
time points. However, there was a significant difference
between the 3 week and 6 month time points.
Of the 21 patients in the overall study, nine had MVO
and 12 did not. Patients with MVO had larger myocar-
dial infarctions, as measured by greater elevation in peak
creatine kinase (3209 ± 2123 vs. 1264 ± 906, p = 0.03)
and a significantly reduced LVEF (41 ± 3 % vs. 49 ± 6,%
p = 0.04) when compared to those without MVO. Other-
wise, the two groups were similar with no significant dif-
ferences in terms of mean age, gender, infarct territory,
presence of multi-vessel coronary artery disease or rates
of major cardiovascular risk factors (See Table 2). MVO
patients also had larger core infarct sizes (as measured
Table 2 Characteristics of patients with and without microvascular obstruction (MVO)
MVO N = 9 No MVO N = 12 p-value
Age (years) 56 ± 11 59 ± 10 0.66
Male (%) 6 (85) 11 (92) 0.83
Culprit vessel
Left anterior descending 4 (44) 4 (33) 0.6
Circumflex 3 (33) 2 (17) 0.37
Right coronary artery 2 (22) 6 (50) 0.19
Multi-vessel coronary artery disease (%) 5 (56) 7 (58) 0.90
DM 3 (33) 5 (17) 0.7
Hypertension 4 (44) 6 (50) 0.8
Smoking 4 (44) 4 (33) 0.6
Dyslipidemia 1 (11) 3 (8) 0.42
Peak CK (AU) 3209 ± 2123 1264 ± 906 0.03
Door to Balloon time (mins) 78 ± 33 67 ± 20 0.5
LVEF 41 ± 3 49 ± 6 0.04
LVEDVi 67 ± 14 69 ± 10 0.7
LVESVi 39 ± 8 35 ± 8 0.55
RVEF 53 ± 7 55 ± 10 0.76
Abbreviations used in the table
DM diabetes mellitus, LVEF left ventricular ejection fraction, LVEDVi (indexed left ventricular end diastolic volume), LVESVi (indexed left ventricular end systolic
volume), RVEF right ventricular ejection fraction
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by LGE) when compared to Non-MVO patients across
all three time points studied. Both MVO (29.2 ± 10.7 %,
21.0 ± 8.6 %, 15.6 ± 7.7 %, p < 0.001, see Fig. 2a) and non-
MVO (9.6 ± 5.8 %, 10.3 ± 7.7 %, 4.4 ± 4.3 %, p = 0.002,
see Fig. 2c) patients had a significant decrease in core in-
farct size over the three time frames. There was a signifi-
cant reduction in peri-infarct zone size over time in the
non-MVO patients (7.0 ± 5.5 %, 7.2 ± 6.5 %, 2.7 ± 2.6 %,
p = 0.01, see Fig. 3c). In contrast, the peri-infarct zone
was not significantly different in patients with MVO
across the three time frames (11.9 ± 6.8 %, 12.2 ± 7.5 %,
10.7 ± 6.6 %, p = 0.77, see Fig. 3a).
MVO patients had significantly elevated T2 values (in
ms) in the peri-infarct zone when compared to the Non-
MVO group at both 48 h (56.3 ± 6.8 vs. 48.4 ± 8.7, p = 0.04)
and 3 weeks post infarct (56.5 ± 7.5 vs. 46.1 ± 7.5, p = 0.02).
In contrast, there was no significant difference in T2 values
in the peri-infarct zone of MVO vs. Non-MVO patients at
the 6 month time frame (39.2 ± 4.7 vs. 38.0 ± 3.3, p = 0.53).
When comparing T2 values in the peri-infarct zone to
the remote myocardium, both MVO and Non-MVO
patients showed a significant increase in T2 values at
48 h (MVO = 56.3 ± 6.8 vs. 42.7 ± 1.8, p <0.01, Non-
MVO = 48.4 ± 8.7 vs. 39.2 ± 2.7, P < 0.01) and 3 weeks
(MVO 56.5 ± 7.5 vs. 39.9 ± 2.4, p <0.01, Non-MVO =
46.1 ± 7.5 vs. 38.9 ± 2.1, P <0.01) but not at 6 months
(MVO 39.2 ± 4.7 vs. 40.0 ± 1.1, p= 0.68 and Non-MVO=
38.0 ± 3.3 vs. 39.6 ± 1.7, p= 0.17).
Inter-observer agreement for the assessment of the PIZ
was excellent (r = 0.96, R2 = 0.93, p <0.001, see Fig. 4a).
Bland-Altman plotting of difference vs. average of obser-
ver 1 vs. observer 2 resulted in the following: Bias = 0.07
and 95 % limits of agreement were between −0.35 and
0.48 (see Fig. 4).
Discussion
Our study is the first to describe the evolution of the
peri-infarct zone post STEMI. Our results demonstrate
that peri-infarct zone, like core infarct size, varies signifi-
cantly depending upon the time point at which it is mea-
sured post STEMI. We also demonstrate that MVO is
associated with a relative persistence of the peri-infarct
zone, whilst non-MVO patients demonstrate a signifi-
cant reduction in the relative size of this zone over time.
Previous studies have shown that the peri-infarct
border zone (‘gray zone’) is an important arrhythmo-
genic substrate. Roes et al., assessed 91 patients post
myocardial infarction who were scheduled for ICD
Fig. 2 Evolution of core infarct size in patients with and without MVO. Panel (a) represents means and standard deviations of core infarct size,
expressed as a percentage of LV mass, for all patients with MVO across the three time frames. Panel (b) represents the T1 weighted IR-GRE Late
gadolinium enhancement images in a patient with MVO. Panel (c) represents means and standard deviations of core infarct size, expressed as a
percentage of LV mass, for all patients without MVO across the three time frames. Panel (d) represents the T1 weighted IR-GRE Late gadolinium
enhancement images in a patient without MVO
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implantation for primary prevention purposes. They
found that the extent of the peri-infarct zone was the
only significant predictor of appropriate ICD therapy,
both on univariate and multivariate analysis [21]. In an-
other recently published study, Yang et al., showed that
peri-infarct zone, as determined by multi-contrast late
enhancement (MCLE) also predicts appropriate ICD
therapy [22]. Yan et al. assessed peri-infarct zone in 144
patients who had late gadolinium enhancement on CMR
in a pattern suggestive of previous myocardial infarction.
Both STEMIs and NSTEMIs were included in this study.
Their multivariate analysis found that the extent of the
peri-infarct zone was an independent predictor for both
cardiovascular and all-cause mortality in their popula-
tion [3]. Our study adds to this body of literature as it
demonstrates that the relative amount of peri-infarct
zone varies over time post STEMI, and suggests that
further studies assessing the peri-infarct zone should
account for this temporal variability.
Microvascular obstruction is a known predictor of
adverse outcomes, including cardiovascular death ost
myocardial infarction. Cochet at al. assessed the
Fig. 3 Evolution of the peri-infarct zone in patients with and without MVO. Panel (a) represents means and standard deviations of peri-infarct
zone size, expressed as a percentage of LV mass, for all patients with MVO across the three time frames. Panel (b) represents T1 weighted IR-GRE
Late gadolinium enhancement images in a patient with MVO with infarct core superimposed in green and PIZ superimposed in yellow. The red
represents area of no reflow or MVO. Directly underneath, a panel displaying T2 maps at the three different time frames for the same patient is
displayed. The yellow arrow indicates the T2 value in the PIZ and the white arrow indicates the T2 value in the remote myocardium. Panel
(c) represents means and standard deviations of peri-infarct zone size, expressed as a percentage of LV mass, for all patients without MVO across
the three time frames. Panel (d) represents the T1 weighted IR-GRE Late gadolinium enhancement images in a patient without MVO with infarct
core superimposed in green and PIZ superimposed in yellow. Directly underneath, a panel displaying T2 maps at the three different time frames
for the same patient is displayed. The yellow arrow indicates the T2 value in the PIZ and the white arrow indicates the T2 value in the remote
myocardium. Of note, the patient with MVO has higher T2 values in the PIZ when compared to the patient without MVO at 48 h and 3 weeks
but not at 6 months. Further, in both patients, T2 values in the PIZ are elevated at the first two time-frames when compared to the remote
myocardium. At 6 months, T2 values are similar in the PIZ and the remote myocardium in both patients. A yellow patch is noted in the septal
region in the patient without MVO at 6 months that is due to artifact from patient motion
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prognostic significance of microvascular obstruction by
cardiac magnetic resonance in 184 patients post acute
myocardial infarction. CMR was performed within a
week following the infarct. On univariate analysis, both
core infarct size and MVO were associated with major
adverse cardiac events (MACE). However, on multivari-
ate analysis, only MVO was found to be an independent
predictor of events [23]. The mechanism by which MVO
leads to its poorer prognosis is currently unknown. In
the era of contemporary cardiovascular care, including
reperfusion therapy, cardiac arrhythmias remain an
important cause of mortality post myocardial infarction
[24]. Numerous studies have linked microvascular
obstruction (MVO) with poor outcomes such as
cardiac arrhythmias and death post myocardial infarc-
tion [4, 15, 25–29]. By demonstrating that patients
with MVO do not see a reduction in peri-infarct zone
over time post myocardial infarction, our findings provide
further insight into how MVO confers poorer prognosis.
Importantly, if these results are replicated in larger studies,
the assessment of the peri-infarct zone may serve as a
surrogate marker for risk, ultimately resulting in potential
treatment implications.
The finding of increased myocardial T2, likely repre-
senting edema in the peri-infarct zone, is driven in part
by a marked local inflammatory response. In keeping
with this, we noted that at 6 months, during the chronic
remodeling phase, T2 values in the peri-infarct zone
normalize to values similar to those in the remote
myocardium. Further, at 6 months, T2 values in the PIZ
are similar between MVO and Non-MVO patients.
Whilst the exact mechanism behind the poor prognosis
observed with MVO remains unclear, we speculate that
a marked early inflammatory response (as measured by
T2 and edema) results in greater tissue injury and exces-
sive replacement fibrosis. This then provides a substrate
for arrhythmias and ongoing remodeling. However, this
theory must be evaluated by future pre-clinical and
large multi-center clinical studies to better assess
mechanism and the link between evolution and size of
the peri-infarct zone, MVO and downstream adverse
clinical outcomes.
A recent systematic review and meta-analysis examin-
ing nine studies with a total of 4686 patients compared
culprit only versus complete revascularization performed
during the primary PCI procedure or during the index
hospitalization in patients presenting with STEMI. The
authors reported that there was no significant difference
in major adverse cardiovascular events at 90 days and
1 year between the two strategies. However, there was a
significant reduction in the rate of repeat revasculariza-
tion at 1 year with a complete revascularization strategy
[30]. In our study, a culprit only revascularization strat-
egy was performed on the study patients. There was no
significant difference in multi-vessel coronary artery dis-
ease between the MVO and non-MVO groups. There-
fore, the differential effect that we reported in terms of
PIZ evolution between the two groups cannot be
explained by group differences in multi-vessel CAD or
revascularization strategy.
There are a number of important limitations of this
study. First, our study was a single center one that involved
a small number of patients. Despite the small numbers, this
is a unique cohort, which has undergone contemporary
management and comprehensive CMR evaluation at mul-
tiple time frames, utilizing well validated CMR sequences
on the same magnet, thus reducing systematic bias in the
reporting of the results. Nonetheless, future larger studies
will be needed in order to determine if the presence of
MVO is an independent predictor for the evolution of the
peri-infarct zone over time, after adjustment for other rele-
vant clinical factors. Second, there is inherent variability in
contouring the myocardium in order to calculate the PIZ.
We therefore assessed inter-observer variability in the de-
termination of the peri-infarct zone. This showed excellent
Fig. 4 Inter-observer agreement in the assessment of peri-infarct
zone. a Pearson correlation comparing observer 1 to observer 2.
b Bland-Altman Plot assessing peri-infarct zone. Dashed lines
represent the 95 % limits of agreement
Roifman et al. BMC Cardiovascular Disorders  (2016) 16:198 Page 7 of 9
inter-observer variability and was similar to results reported
by other groups [31]. Third, determination of the size of
the PIZ may be prone to partial volume averaging artifact
from the infarct core [31]. Further, T2 values measured in
the PIZ may also partially reflect this artifact. Future work
using high resolution late gadolinium enhancement
sequences may help address this issue.
Conclusions
Both infarct size and peri-infarct zone (‘gray zone’) evolve
over time following STEMI. In patients with MVO, there
was a lack of regression of the peri-infarct zone.
Abbreviations
AMI: Acute myocardial infarction; ANOVA: Analysis of variance; CIS: Core
infarct size; CMR: Cardiac magnetic resonance; GZ: Gray zone;
ICD: Implantable cardioverter defibrillator; MVO: Microvascular obstruction;
PCI: Percutaneous coronary intervention; PIZ: Peri-infarct zone; STEMI: ST
elevation myocardial Infarction
Acknowledgements
This research was funded by a Canadian Institutes for Health Research
operating grant. Dr. Kim A. Connelly is supported by a Canadian Institutes of
Health Research New Investigator Award. Dr. Graham A. Wright is supported
by a Canada Research Chair in Imaging for Cardiovascular Therapeutics.
Research support has also been provided from GE Healthcare. The funding
sources had no role in the design, collection, analysis and interpretation of
data, in the writing of the manuscript and in the decision to submit the
manuscript for publication.
Availability of data and materials
Sunnybrook REB and legal services do not allow for the publication the raw
patient data on public domains. In the case of individual queries regarding
data sharing, the corresponding author would be happy to entertain these
requests, and is interested in sharing the de-identified data, pending
approval by the REB and Sunnybrook legal services of the specific request.
Author’s contributions
Each author 1) made substantial contributions to conception and design, or
acquisition of data, or analysis and interpretation of data; 2) has been involved
in drafting the manuscript or revising it critically for important intellectual
content; and 3) has given final approval of the version to be published.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
As part of consenting to enter this study, each patient consented to their
de-identified/coded data to be used for publication purposes.
Ethics approval and consent to participate
This project was approved by the Research Ethics Board (REB) at Sunnybrook
Health Sciences Centre. Each patient provided written consent to participate
in this study.
Author details
1Sunnybrook Research Institute, Schulich Heart Program, Sunnybrook Health
Sciences Centre and the University of Toronto, 2075 Bayview Avenue, room
M 315b, Toronto, ON M4N-3M5, Canada. 2Keenan Research Centre for
Biomedical Science and Li Ka Shing Knowledge Institute of St. Michael’s
Hospital, The University of Toronto, Toronto, ON, Canada. 3Division of
Cardiothoracic Imaging, Department of Medical Imaging, Sunnybrook Health
Sciences Centre and the University of Toronto, Toronto, ON, Canada.
4Physical Sciences Platform, Sunnybrook Research Institute, Sunnybrook
Health Sciences Centre and the University of Toronto, Toronto, ON, Canada.
5Department of Medical Biophysics, University of Toronto, Toronto, ON,
Canada.
Received: 3 March 2016 Accepted: 30 September 2016
References
1. Schulz-Menger J, Bluemke DA, Bremerich J, Flamm SD, Fogel MA, Friedrich
MG, Kim RJ, von Knobelsdorff-Brenkenhoff F, Kramer CM, Pennell DJ, et al.
Standardized image interpretation and post processing in cardiovascular
magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR)
board of trustees task force on standardized post processing. J Cardiovasc
Magn Reson. 2013;15:35.
2. Kawel-Boehm N, Maceira A, Valsangiacomo-Buechel ER, Vogel-Claussen J,
Turkbey EB, Williams R, Plein S, Tee M, Eng J, Bluemke DA. Normal values for
cardiovascular magnetic resonance in adults and children. J Cardiovasc
Magn Reson. 2015;17:29.
3. Yan AT, Shayne AJ, Brown KA, Gupta SN, Chan CW, Luu TM, Di Carli MF,
Reynolds HG, Stevenson WG, Kwong RY. Characterization of the peri-infarct
zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful
predictor of post-myocardial infarction mortality. Circulation. 2006;114:32–9.
4. Yan AT, Gibson CM, Larose E, Anavekar NS, Tsang S, Solomon SD, Reynolds
G, Kwong RY. Characterization of microvascular dysfunction after acute
myocardial infarction by cardiovascular magnetic resonance first-pass
perfusion and late gadolinium enhancement imaging. J Cardiovasc Magn
Reson. 2006;8:831–7.
5. Judd RM, Kim RJ. Can cardiac MRI predict outcome in patients at risk for
unrecognized myocardial infarction? Nat Clin Pract Cardiovasc Med. 2006;3:652–3.
6. Klocke FJ, Wu E, Lee DC. “Shades of gray” in cardiac magnetic resonance
images of infarcted myocardium: can they tell us what we’d like them to?
Circulation. 2006;114:8–10.
7. Yao JA, Hussain W, Patel P, Peters NS, Boyden PA, Wit AL. Remodeling of
gap junctional channel function in epicardial border zone of healing canine
infarcts. Circ Res. 2003;92:437–43.
8. Ursell PC, Gardner PI, Albala A, Fenoglio Jr JJ, Wit AL. Structural and
electrophysiological changes in the epicardial border zone of canine
myocardial infarcts during infarct healing. Circ Res. 1985;56:436–51.
9. Bodi V, Sanchis J, Nunez J, Mainar L, Lopez-Lereu MP, Monmeneu JV, Rumiz
E, Chaustre F, Trapero I, Husser O, et al. Prognostic value of a
comprehensive cardiac magnetic resonance assessment soon after a first
ST-segment elevation myocardial infarction. J Am Coll Cardiol Img.
2009;2:835–42.
10. Bodi V, Rumiz E, Merlos P, Nunez J, Lopez-Lereu MP, Monmeneu JV,
Chaustre F, Moratal D, Trapero I, Blasco ML, et al. One-week and 6-month
cardiovascular magnetic resonance outcome of the pharmacoinvasive
strategy and primary angioplasty for the reperfusion of ST-segment
elevation myocardial infarction. Rev Esp Cardiol. 2011;64:111–20.
11. Bruder O, Breuckmann F, Jensen C, Jochims M, Naber CK, Barkhausen J, Erbel R,
Sabin GV. Prognostic impact of contrast-enhanced CMR early after acute ST
segment elevation myocardial infarction (STEMI) in a regional STEMI network:
results of the “Herzinfarktverbund Essen”. Herz. 2008;33:136–42.
12. Choi CJ, Haji-Momenian S, Dimaria JM, Epstein FH, Bove CM, Rogers WJ,
Kramer CM. Infarct involution and improved function during healing of
acute myocardial infarction: the role of microvascular obstruction. J
Cardiovasc Magn Reson. 2004;6:917–25.
13. Choi JW, Gibson CM, Murphy SA, Davidson CJ, Kim RJ, Ricciardi MJ.
Myonecrosis following stent placement: association between impaired TIMI
myocardial perfusion grade and MRI visualization of microinfarction.
Catheter Cardiovasc Interv. 2004;61:472–6.
14. Zia MI, Ghugre NR, Connelly KA, Strauss BH, Sparkes JD, Dick AJ, Wright GA.
Characterizing myocardial edema and hemorrhage using quantitative T2
and T2* mapping at multiple time intervals post ST-segment elevation
myocardial infarction. Circ Cardiovasc Imaging. 2012;5:566–72.
15. Zia MI, Ghugre NR, Connelly KA, Joshi SB, Strauss BH, Cohen EA, Wright GA,
Dick AJ. Thrombus aspiration during primary percutaneous coronary
intervention is associated with reduced myocardial edema, hemorrhage,
microvascular obstruction and left ventricular remodeling. J Cardiovasc
Magn Reson. 2012;14:19.
16. Roifman I, Ghugre N, Zia MI, Farkouh ME, Zavodni A, Wright GA, Connelly
KA. Diabetes is an independent predictor of right ventricular dysfunction
post ST-elevation myocardial infarction. Cardiovasc Diabetol. 2016;15:34.
17. Roifman I, Zia MI, Zavodni A, Wolff R, Ghugre NR, Leber AW, Dick AJ, Wright
GA, Connelly KA. Evolution of right ventricular function post-acute ST
elevation myocardial infarction. J Magn Reson Imaging. 2014;40:709–14.
Roifman et al. BMC Cardiovascular Disorders  (2016) 16:198 Page 8 of 9
18. Schmidt A, Azevedo CF, Cheng A, Gupta SN, Bluemke DA, Foo TK,
Gerstenblith G, Weiss RG, Marban E, Tomaselli GF, et al. Infarct tissue
heterogeneity by magnetic resonance imaging identifies enhanced cardiac
arrhythmia susceptibility in patients with left ventricular dysfunction.
Circulation. 2007;115:2006–14.
19. Detsky JS, Paul G, Dick AJ, Wright GA. Reproducible classification of infarct
heterogeneity using fuzzy clustering on multicontrast delayed enhancement
magnetic resonance images. IEEE Trans Med Imaging. 2009;28:1606–14.
20. Zia MI, Ghugre NR, Roifman I, Strauss BH, Walcarius R, Mohammed M, Sparkes
JD, Dick AJ, Wright GA, Connelly KA. Comparison of the frequencies of
myocardial edema determined by cardiac magnetic resonance in diabetic
versus nondiabetic patients having percutaneous coronary intervention for ST
elevation myocardial infarction. Am J Cardiol. 2014;113:607–12.
21. Roes SD, Borleffs CJ, van der Geest RJ, Westenberg JJ, Marsan NA, Kaandorp
TA, Reiber JH, Zeppenfeld K, Lamb HJ, de Roos A, et al. Infarct tissue
heterogeneity assessed with contrast-enhanced MRI predicts spontaneous
ventricular arrhythmia in patients with ischemic cardiomyopathy and
implantable cardioverter-defibrillator. Circ Cardiovasc Imaging. 2009;2:183–90.
22. Yang Y, Connelly KA, Zeidan-Shwiri T, Lu Y, Paul G, Roifman I, Zia MI,
Graham JJ, Dick AJ, Crystal E, Wright GA. Multi-contrast late enhancement
CMR determined gray zone and papillary muscle involvement predict
appropriate ICD therapy in patients with ischemic heart disease. J
Cardiovasc Magn Reson. 2013;15:57.
23. Cochet AA, Lorgis L, Lalande A, Zeller M, Beer JC, Walker PM, Touzery C, Wolf
JE, Brunotte F, Cottin Y. Major prognostic impact of persistent microvascular
obstruction as assessed by contrast-enhanced cardiac magnetic resonance in
reperfused acute myocardial infarction. Eur Radiol. 2009;19:2117–26.
24. Solomon SD, Zelenkofske S, McMurray JJ, Finn PV, Velazquez E, Ertl G,
Harsanyi A, Rouleau JL, Maggioni A, Kober L, et al. Sudden death in patients
with myocardial infarction and left ventricular dysfunction, heart failure, or
both. N Engl J Med. 2005;352:2581–8.
25. Klem I, Kim RJ. Assessment of microvascular injury after acute myocardial infarction:
importance of the area at risk. Nat Clin Pract Cardiovasc Med. 2008;5:756–7.
26. de Waha S, Desch S, Eitel I, Fuernau G, Lurz P, Leuschner A, Grothoff M, Gutberlet
M, Schuler G, Thiele H. Relationship and prognostic value of microvascular
obstruction and infarct size in ST-elevation myocardial infarction as visualized by
magnetic resonance imaging. Clin Res Cardiol. 2012;101:487–95.
27. Klug G, Mayr A, Schenk S, Esterhammer R, Schocke M, Nocker M, Jaschke W,
Pachinger O, Metzler B. Prognostic value at 5 years of microvascular
obstruction after acute myocardial infarction assessed by cardiovascular
magnetic resonance. J Cardiovasc Magn Reson. 2012;14:46.
28. Malek LA, Spiewak M, Klopotowski M, Misko J, Ruzyllo W, Witkowski A. The
size does not matter - the presence of microvascular obstruction but not its
extent corresponds to larger infarct size in reperfused STEMI. Eur J Radiol.
2012;81:2839–43.
29. Wong DT, Richardson JD, Puri R, Nelson AJ, Bertaso AG, Teo KS, Worthley
MI, Worthley SG. The role of cardiac magnetic resonance imaging following
acute myocardial infarction. Eur Radiol. 2012;22:1757–68.
30. Moretti C, D’Ascenzo F, Quadri G, Omede P, Montefusco A, Taha S, Cerrato
E, Colaci C, Chen SL, Biondi-Zoccai G, Gaita F. Management of multivessel
coronary disease in STEMI patients: a systematic review and meta-analysis.
Int J Cardiol. 2015;179:552–7.
31. Schelbert EB, Hsu LY, Anderson SA, Mohanty BD, Karim SM, Kellman P, Aletras
AH, Arai AE. Late gadolinium-enhancement cardiac magnetic resonance
identifies postinfarction myocardial fibrosis and the border zone at the near
cellular level in ex vivo rat heart. Circ Cardiovasc Imaging. 2010;3:743–52.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Roifman et al. BMC Cardiovascular Disorders  (2016) 16:198 Page 9 of 9
